← Russell 3000 cross-section

TVTX Travere Therapeutics, Inc.

Trailing twelve months to 2026-06-30 · as filed 2026-08-04, not restated
Healthcare

Scale

Market cap
$6.3bn
Revenue TTM
$591m
Net income TTM
$-44m
Free cash flow
Composite score
Sector rank
#938

Valuation

P / E
EV / EBITDA
262.5
EV / sales
10.2
FCF yield
Earnings yield vs 10-yr
-5.42pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
-7.3%
EBITDA margin
3.9%
ROE
-177.2%
ROIC
Revenue growth
77.1%

Insider activity, last 90 days

Net open-market
$-1.36m
Buyers
0
Sellers
3

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

Under the Everest Agreement, we paid Everest an upfront payment of $112.5 million in July 2026 and Everest is eligible to receive up to approximately $1.03 billion in additional development, regulatory and commercial milestone payments, as well as tiered royalties on net sales of civorebrutinib products in the Territory. Accordingly, Thiola EC is subject to generic competitio n. Results of Operations Results of operations for the three and six months ended June 30, 2026 compared to the three and six months ended June 30, 2025 Revenue The following table provides information regarding revenue, including net product sales and license and collaboration revenue ( in thousands ): Net product sale …Travere Therapeutics, Inc., 10-Q, period ended 2026-06-30, filed 2026-08-04

Read the full passage →